A new study has said that a 5-day course of Molnupiravir could reduce deaths and prove effective and safe at relatively lower costs, in adults and non-pregnant COVID-19 unvaccinated patients at increased risk of severity or needing hospitalization.
The study also said that the drug, as compared to others, may be more effective against the Omicron variant.
Molnupiravir is a new oral antiviral drug that has recently received emergency use authorization in several countries including India but it has not been included in the national COVID-19 treatment protocol yet.